Return on Investment of 10-Valent Pneumococcal Conjugate Vaccine in Ecuador From 2010 to 2030

Economía y empresa

• Ecuador 73%
• Vaccine 72%
• Return on Investment 55%
• Value of Statistical Life 23%
• Immunization Program 23%
• Cost of Illness 22%
• Immunization 18%
• Costs 16%
• Economic Benefits 13%
• Willingness-to-pay 12%
• Time Series Analysis 11%
• Cold Chain 10%
• Injection 8%
• Policymaker 6%
• Personnel 5%
• Resources 4%
• Productivity 4%

Medicina y ciencias biológicas

• 10-valent pneumococcal conjugate vaccine 100%
• Ecuador 83%
• Costs and Cost Analysis 23%
• Value of Life 21%
• Immunization Programs 17%
• Cost of Illness 17%
• Cost-Benefit Analysis 12%
• Immunization 12%
• Economics 11%
• Refrigeration 10%
• Pneumococcal Vaccines 9%
• Conjugate Vaccines 9%
• Pneumococcal Infections 9%
• Syringes 8%
• Administrative Personnel 7%
• Vaccines 5%
• Occupational Groups 5%
• Maintenance 5%
• Equipment and Supplies 4%
• Injections 4%
• Child 3%
• Therapeutics 1%

Ciencias sociales

• Ecuador 63%
• costs 29%
• illness 11%
• wage costs 11%
• willingness to pay 9%
• time series analysis 9%
• economics 6%
• productivity 6%
• society 5%
• resources 3%